 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

1832 Asset Management L.P. lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN  Free Report) by 75.1% during the 2nd quarter, according to its most recent 13F filing...

1832 Asset Management L.P. Sells 6,679 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

TARRYTOWN, N.Y., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a conference call and simultaneous webcast to provide an update on the company's...

Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio

Regeneron Pharmaceuticals (NASDAQ:REGN  Get Free Report)s stock had its buy rating reaffirmed by investment analysts at Truist Financial in a note issued to investors on...

Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Reaffirmed by Truist Financial

Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 35th Annual Healthcare Conference (Transcript...

Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 35th Annual Healthcare Conference (Transcript)

NOTUS trial met its primary endpoint with overwhelming efficacy, showing Dupixent significantly reduced exacerbations by 34% compared to placebo in patients with moderate-to-severe COPD with evidence...

Dupixent  (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced the second Dupixent (dupilumab) Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that...

Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder

Profund Advisors LLC raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN  Free Report) by 8.9% in the second quarter, according to its most recent 13F filing with the...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Raised by Profund Advisors LLC

Quadrant Capital Group LLC lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN  Free Report) by 4.7% during the 2nd quarter, according to its most recent filing...

Quadrant Capital Group LLC Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

How Is The Market Feeling About Regeneron Pharmaceuticals?

Intech Investment Management LLC reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN  Free Report) by 84.4% during the 2nd quarter, according to the company in its most recent...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Reduced by Intech Investment Management LLC

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Watchers	15,504
52-Wk Low	$668.00
52-Wk High	$853.97

Market Cap	$91.05B
Volume (M)	554,087.00
52-Wk High	$853.97
52-Wk Low	$668.00

Current Price	$835.75
Prev Close	$820.90
Open	$825.55
Dividend Yield	0.00%
50-Day Moving Average	$812.88
Beta	0.59
Avg. Volume	529,097.71
PE Ratio	23.84

52-Week High	$853.97
52-Week Low	$668.00
Market Capitalization	$91.05B
EPS	$35.06
Price to Book	3.65
Revenue Per Employee	$1.11M
Enterprise Value/EBITDA	17.86

REGN Regeneron Pharmaceuticals, Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals